SAN FRANCISCO

Genoox, the healthcare technology company on a mission to make it easier for doctors, clinicians and researchers to run clinical genetic applications and act on genetic sequencing results, today announced major updates to its platform. The new capabilities use artificial intelligence-based tools to promote regular and periodic genomic data reanalysis and data aggregation to quicken diagnoses for patients based on new clinical evidence, and improve diagnosis yield for undiagnosed cases.

With the advance of NGS technology and a growing body of genomics research, there is an urgent need for data reanalysis technology that continuously scans new research and clinical evidence, which Genoox fills. The platform can automatically alert customers when genetic samples contain mutations that were previously unidentified or unknown, instead of labs needing to constantly run manual tests when new clinical evidence is released and classified as actionable.

“As genomic sequencing has reached incredible heights over the last decade, keeping pace with new evidence and research has become a primary goal for genomics,” said Amir Trabelsi, CEO and co-founder of Genoox. “There is a technology disconnect between academic literature and real-world applications of NGS, and the Genoox platform answers this need for so many audiences: sick patients with unidentified conditions, the families of deceased people who are looking for answers, and future patients who will carry the same mutations.”

“The success of modern genomic testing relies on sophisticated informatics techniques for genome interpretation that allows us to significantly improve our understanding of genetic variants that contribute to rare diseases and sudden death,” said Ali Torkamani, PhD at Scripps Research Translational Institute. “As genomics surges forward, it’s critical to keep pace with updates of new clinical evidences and learn from historical data, using data aggregation technology that builds a broad, applicable body of insights for researchers and the medical community. We’re excited by the possibilities our collaboration with Genoox holds for advancing science and medicine.”

About Genoox
Genoox is a genomic analysis company on a mission to make clinical genetic sequencing more accessible and affordable. Using its cloud based platform, Genoox manages the entire genetic sequencing process from raw data collection to the delivery of clinical actionable insights. By automating data interpretation and providing millions of in-house and public data points through a proprietary search engine, Genoox aims to improve patient outcomes with increased accuracy and efficiency, enabling personalized medicine. Users across research, clinical and medical facilities can then securely share complex clinical research using a set of customizable tools developed to analyze data and generate actionable reports.

About Scripps Research
Scripps Research ranks as the most influential scientific organization in the world, unparalleled in propelling innovation in science and medicine. Our unique structure merges foundational studies in biology, chemistry and computer science with translational science to produce the next generation of drugs and advances in digital and precision medicine. On campuses in California and Florida, scientists in the institute’s five bicoastal academic research departments work hand-in-hand with researchers of the Scripps Research Translational Institute and Calibr. Together, we cultivate the next generation of scientific leaders and expand the frontiers of knowledge to drive innovation that improves lives around the planet.